Analysis and Commentary 1/16/21 Analysis and Commentary 1/16/21 Supporting a Budget Increase for FDA for FY 22 Read More Analysis and Commentary 1/8/21 Analysis and Commentary 1/8/21 Now We Know Who'll Be in Charge Read More Analysis and Commentary 12/10/20 Analysis and Commentary 12/10/20 COVID-19 Vaccine Update: A Briefing from the FDA Read More Analysis and Commentary 12/5/20 Analysis and Commentary 12/5/20 CDRH Update and Future Priorities Read More Analysis and Commentary 11/19/20 Analysis and Commentary 11/19/20 Time to Give Thanks -- Once Again Read More Analysis and Commentary 11/12/20 Analysis and Commentary 11/12/20 Where $40 Million Might Go for FY 21 Read More Analysis and Commentary 11/8/20 Analysis and Commentary 11/8/20 What Happens in the Next Few Months? Read More Analysis and Commentary 10/31/20 Analysis and Commentary 10/31/20 Whether There Is or Whether There Isn't Read More Analysis and Commentary 10/24/20 Analysis and Commentary 10/24/20 FY 21, FY 22 Appropriations and CDER Priorities Read More Analysis and Commentary 10/16/20 Analysis and Commentary 10/16/20 Future Changes in Congressional Committees and the FDA Read More Analysis and Commentary 10/9/20 Analysis and Commentary 10/9/20 Webinar on Budget, Workload, and Other Priorities for CDER Read More Analysis and Commentary 10/1/20 Analysis and Commentary 10/1/20 Understanding the Short-Term CR Read More Analysis and Commentary 9/25/20 Analysis and Commentary 9/25/20 How FDA is Funded, ... and Why Read More Analysis and Commentary 9/18/20 Analysis and Commentary 9/18/20 Public Trust in the US FDA Read More Analysis and Commentary 9/3/20 Analysis and Commentary 9/3/20 Understanding Tom Frieden's Proposed HDO Read More Analysis and Commentary 8/14/20 Analysis and Commentary 8/14/20 "Somehow the CR Will Pass", But When? Read More Analysis and Commentary 8/7/20 Analysis and Commentary 8/7/20 CDER Priorities: During the Pandemic and for 2021 Read More Analysis and Commentary 8/1/20 Analysis and Commentary 8/1/20 About the Alliance for a Stronger FDA Read More Analysis and Commentary 7/18/20 Analysis and Commentary 7/18/20 Why No Movement in the Senate? Read More Analysis and Commentary 7/10/20 Analysis and Commentary 7/10/20 CBER Director on COVID-19 and Vaccine Development Read More Newer Posts Older Posts
Analysis and Commentary 1/16/21 Analysis and Commentary 1/16/21 Supporting a Budget Increase for FDA for FY 22 Read More
Analysis and Commentary 1/8/21 Analysis and Commentary 1/8/21 Now We Know Who'll Be in Charge Read More
Analysis and Commentary 12/10/20 Analysis and Commentary 12/10/20 COVID-19 Vaccine Update: A Briefing from the FDA Read More
Analysis and Commentary 12/5/20 Analysis and Commentary 12/5/20 CDRH Update and Future Priorities Read More
Analysis and Commentary 11/19/20 Analysis and Commentary 11/19/20 Time to Give Thanks -- Once Again Read More
Analysis and Commentary 11/12/20 Analysis and Commentary 11/12/20 Where $40 Million Might Go for FY 21 Read More
Analysis and Commentary 11/8/20 Analysis and Commentary 11/8/20 What Happens in the Next Few Months? Read More
Analysis and Commentary 10/31/20 Analysis and Commentary 10/31/20 Whether There Is or Whether There Isn't Read More
Analysis and Commentary 10/24/20 Analysis and Commentary 10/24/20 FY 21, FY 22 Appropriations and CDER Priorities Read More
Analysis and Commentary 10/16/20 Analysis and Commentary 10/16/20 Future Changes in Congressional Committees and the FDA Read More
Analysis and Commentary 10/9/20 Analysis and Commentary 10/9/20 Webinar on Budget, Workload, and Other Priorities for CDER Read More
Analysis and Commentary 10/1/20 Analysis and Commentary 10/1/20 Understanding the Short-Term CR Read More
Analysis and Commentary 9/25/20 Analysis and Commentary 9/25/20 How FDA is Funded, ... and Why Read More
Analysis and Commentary 9/3/20 Analysis and Commentary 9/3/20 Understanding Tom Frieden's Proposed HDO Read More
Analysis and Commentary 8/14/20 Analysis and Commentary 8/14/20 "Somehow the CR Will Pass", But When? Read More
Analysis and Commentary 8/7/20 Analysis and Commentary 8/7/20 CDER Priorities: During the Pandemic and for 2021 Read More
Analysis and Commentary 8/1/20 Analysis and Commentary 8/1/20 About the Alliance for a Stronger FDA Read More
Analysis and Commentary 7/18/20 Analysis and Commentary 7/18/20 Why No Movement in the Senate? Read More
Analysis and Commentary 7/10/20 Analysis and Commentary 7/10/20 CBER Director on COVID-19 and Vaccine Development Read More
